Unasnemab clinical trials
Also written MT-3921.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses unasnemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Mitsubishi Tanabe Pharma Corporation (2) · Tanabe Pharma America, Inc. (1) · Mitsubishi Tanabe Pharma America Inc. (1)
Studies
Open first, then newest update. How each study uses unasnemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord InjuryCompletedPhase 2Tanabe Pharma America, Inc.NCT04683848Written as MT-3921
- A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT05240612Written as MT-3921
- Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord InjuryCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04096950Written as MT-3921 Low dose
- A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT05396235Written as MT-3921
Codes
What other systems call unasnemab · ClinicalTrials.gg INT018451
- UNII (FDA) XB2155292YUNASNEMABOne source FDA
- NCI Thesaurus C179131UnasnemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XB2155292Y | UNASNEMAB | One source FDA |
| NCI Thesaurus | C179131 | Unasnemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.